Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Kura Oncology (NASDAQ:KURA) to a strong-buy rating in a research report report published on Tuesday morning, Zacks.com reports.

KURA has been the topic of several other reports. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $17.78 on Tuesday. The firm has a market capitalization of $1.35 billion, a P/E ratio of -8.19 and a beta of 0.84. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The stock’s 50-day simple moving average is $19.38 and its two-hundred day simple moving average is $20.11. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.04. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.53) EPS. As a group, equities analysts anticipate that Kura Oncology will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Avoro Capital Advisors LLC increased its position in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares in the last quarter. Affinity Asset Advisors LLC increased its position in Kura Oncology by 281.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after buying an additional 538,957 shares in the last quarter. Sofinnova Investments Inc. increased its position in Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after buying an additional 323,303 shares in the last quarter. Finally, Armistice Capital LLC increased its position in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.